Presse Medicale最新文献

{"title":"Heart failure: A major public health problem","authors":"Claude Daubert","doi":"10.1016/j.lpm.2024.104224","DOIUrl":"10.1016/j.lpm.2024.104224","url":null,"abstract":"","PeriodicalId":20530,"journal":{"name":"Presse Medicale","volume":"53 1","pages":"Article 104224"},"PeriodicalIF":2.7,"publicationDate":"2024-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139716368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Towards etiological treatments in cardiomyopathies","authors":"Olivier Lairez ,&nbsp;Pauline Fournier ,&nbsp;Romain Itier ,&nbsp;Bérengère Bachelet ,&nbsp;Antoine Huart ,&nbsp;Eve Cariou","doi":"10.1016/j.lpm.2024.104223","DOIUrl":"10.1016/j.lpm.2024.104223","url":null,"abstract":"<div><p>This review proposes to look at the evolution of cardiomyopathy treatments in the light of advances in diagnostic techniques, which have enabled to move from a mechanistic to a phenotypic and then etiological approach. The article goes beyond the ejection fraction approach, and look at new therapies that target the pathophysiological pathways of cardiomyopathies, either by targeting the phenotype, or by targeting the etiology. The evolution of HCM treatments is detailed, culminating in the latest etiological treatments such as mavacamten in sarcomeric HCM, tafamidis in transthyretin cardiac amyloidosis and migalastat in Fabry disease. Myosin stimulators are reviewed in the treatment of DCM, before opening perspectives for gene therapy, which proposes direct treatment of the culprit mutation.</p></div>","PeriodicalId":20530,"journal":{"name":"Presse Medicale","volume":"53 1","pages":"Article 104223"},"PeriodicalIF":2.7,"publicationDate":"2024-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0755498224000010/pdfft?md5=6d8b5a4c246ae1a0c68755ee9e493237&pid=1-s2.0-S0755498224000010-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139681424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Imbalance of TH17/TREG cells in Tunisian patients with systemic sclerosis","authors":"Gabsi Amira ,&nbsp;Dlala Akram ,&nbsp;Missaoui Fadoua ,&nbsp;Neili Bilel ,&nbsp;Boutaba Alya ,&nbsp;Ben salem Khalil ,&nbsp;Smiti Khanfir Monia ,&nbsp;Said Fatma ,&nbsp;Houman Mohamed Habib ,&nbsp;Bardin Nathalie ,&nbsp;Triki Marrakchi Raja","doi":"10.1016/j.lpm.2023.104221","DOIUrl":"10.1016/j.lpm.2023.104221","url":null,"abstract":"<div><p>Fibrosis is a pathological manifestation in which connective tissue replaces normal one. It can affect many tissues from the skin to internal organs such as the lungs. Manifestations of pulmonary involvement can be pulmonary arterial hypertension or pulmonary fibrosis. The latter one is currently the leading cause of death in various autoimmune diseases, including systemic sclerosis.</p><p>Our study group consists of 50 patients with systemic sclerosis: 24 with limited cutaneous form and 26 with diffuse cutaneous form. This cohort was compared to 50 healthy controls (age and sex matched); our aim is to explore the distribution of TH17 cells (TH17) as well as regulatory T cells (TREG) and study their correlation with the disease's progress. Our results show an increase for IL17A in patients compared to controls and that this increase is correlated with a specific clinical involvement: Pulmonary fibrosis. This correlation suggests a crucial role of IL17A in fibrosis especially in systemic sclerosis. In addition, we have shown that the percentages of TH17 cells are higher in patients; however, the percentages of TREG cells are similar between patients and controls. A study of TREG cell activity showed that TREG lost suppressive activity by inactivating the FOXP3 transcription factor. This proves that despite their presence, TREG does not adequately carry out their regulatory activity. Finally, we analyzed the correlation between TH17/TREG and clinical damage; the results show a positive correlation with pulmonary involvement proving the role of TH17/TREG balance in induced fibrosis in systemic sclerosis. No significative difference was observed, for all the parameters, between the two different forms of the disease.</p><p>In conclusion, the results associated with the TH17/TREG scale and their correlations with fibrosis in systemic sclerosis open a way for new tools to manage this autoimmune disease, which up to today has neither treatment nor accurate diagnosis.</p></div>","PeriodicalId":20530,"journal":{"name":"Presse Medicale","volume":"53 1","pages":"Article 104221"},"PeriodicalIF":2.7,"publicationDate":"2023-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139074933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"All you need to know about VIPoma: Review on the latest studies","authors":"Emija Nikola Karele","doi":"10.1016/j.lpm.2023.104222","DOIUrl":"10.1016/j.lpm.2023.104222","url":null,"abstract":"<div><p><span><span>Vasoactive intestinal peptide<span> secreting tumor (VIPoma) is a rare mostly malignant neuroendocrine tumor<span> that is characterized by watery diarrhea, hypokalemia<span> and achlorhydria<span> due to the nonregulated increased secretion of VIP. VIPomas ar diagnosed by the presence of the most common symptoms, laboratory analysis of blood and stool, radiological imaging and immunohistochemical findings. Primary treatment includes fluid replacement, </span></span></span></span></span>electrolyte balance<span> correction, pharmacological treatment with somatostatin analogs, surgical resection and chemotherapy. This review aims to provide an insight into the latest research on </span></span>VIPoma<span> epidemiology<span>, pathophysiology, diagnostics and treatment.</span></span></p></div>","PeriodicalId":20530,"journal":{"name":"Presse Medicale","volume":"53 2","pages":"Article 104222"},"PeriodicalIF":2.7,"publicationDate":"2023-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138804437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"XBB and BQ.1, the two Omicron cousins dominating globally: Is it the time we should think again?","authors":"Rubai Ahmed,&nbsp;Sovan Samanta,&nbsp;Jhimli Banerjee,&nbsp;Sandeep Kumar Dash","doi":"10.1016/j.lpm.2023.104220","DOIUrl":"10.1016/j.lpm.2023.104220","url":null,"abstract":"","PeriodicalId":20530,"journal":{"name":"Presse Medicale","volume":"53 1","pages":"Article 104220"},"PeriodicalIF":2.7,"publicationDate":"2023-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138804449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chronic heart failure with reduced EF: A decade of major pharmacological innovations","authors":"Jean-Noël Trochu","doi":"10.1016/j.lpm.2023.104219","DOIUrl":"10.1016/j.lpm.2023.104219","url":null,"abstract":"<div><h3>Background and objectives</h3><p>Because of its severity, prevalence, and medical economic<span> importance, heart failure is a chronic disease that is the subject of intense medical research<span>. The aim of this article was to review the therapeutic innovations of the last decade that have been incorporated into the latest international recommendations for the treatment of heart failure.</span></span></p></div><div><h3>Method</h3><p>Review of literature and current guidelines.</p></div><div><h3>Conclusion</h3><p>The results of the clinical trials<span> reviewed here represent major advances that will have a significant impact on quality of life<span>, survival, rehospitalisation and, for certain treatments, a beneficial joint effect on commonly associated comorbidities such as diabetes and chronic renal failure.</span></span></p></div>","PeriodicalId":20530,"journal":{"name":"Presse Medicale","volume":"53 1","pages":"Article 104219"},"PeriodicalIF":2.7,"publicationDate":"2023-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138804444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Main nose-throat-ears, and ophthalmic features in sickle cell disease children","authors":"Léon Tshilolo ,&nbsp;Joseph Kelekele","doi":"10.1016/j.lpm.2023.104210","DOIUrl":"10.1016/j.lpm.2023.104210","url":null,"abstract":"","PeriodicalId":20530,"journal":{"name":"Presse Medicale","volume":"52 4","pages":"Article 104210"},"PeriodicalIF":2.7,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138047810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gene-addition/editing therapy in sickle cell disease","authors":"Galia Pollock ,&nbsp;Olivier Negre ,&nbsp;Jean-Antoine Ribeil","doi":"10.1016/j.lpm.2023.104214","DOIUrl":"10.1016/j.lpm.2023.104214","url":null,"abstract":"<div><p><span>Gene therapy is an innovative strategy that offers potential cure for patients with sickle cell disease, and no appropriate donor for transplant consideration. While we await long term data from these </span>clinical trials<span>, we remain optimistic that gene therapy will become a standard of care for curative treatment in sickle cell disease. As gene therapy becomes a standard of treatment in sickle cell disease, we must also acknowledge the potential for financial burden to patients. We also must acknowledge the prevalence of sickle cell disease in low-resource settings. Hopefully, as we learn more about gene therapy, we can assess ways to overcome the financial toxicity that comes with this therapy.</span></p></div>","PeriodicalId":20530,"journal":{"name":"Presse Medicale","volume":"52 4","pages":"Article 104214"},"PeriodicalIF":2.7,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138434920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The liver in sickle cell disease","authors":"Christophe Duvoux ,&nbsp;Lorraine Blaise ,&nbsp;Jean-Jacques Matimbo ,&nbsp;Francky Mubenga ,&nbsp;Norbert Ngongang ,&nbsp;Monika Hurtova ,&nbsp;Alexis Laurent ,&nbsp;Jérémy Augustin ,&nbsp;Julien Calderaro ,&nbsp;Edouard Reizine ,&nbsp;Alain Luciani ,&nbsp;Anoosha Habibi ,&nbsp;Dora Bachir ,&nbsp;Geoffroy Vole ,&nbsp;Justine Gellen-Dautremer ,&nbsp;Vincent Leroy ,&nbsp;Eric Levesque ,&nbsp;Pablo Bartolucci","doi":"10.1016/j.lpm.2023.104212","DOIUrl":"10.1016/j.lpm.2023.104212","url":null,"abstract":"<div><p>Liver involvement in SCD<span><span><span> patients is frequent but often misdiagnosed or underestimated, except in case of advanced liver diseases. Because of so far poorly recognized forms of chronic SCD-related vascular injury<span> that can silently evolved towards end stages or facilitate ACLF, any persisting </span></span>liver function tests<span> abnormalities should be carefully investigated, following the above proposed algorithm. Work up and management must be considered multidisciplinary in relationship with a Hepatologist. Early SCD hepatopathy should prompt revision of SCD management to prevent further liver injury and decompensation, discussing transfusion exchanges<span> and hydro urea when not yet initiated, and control for any cofactor of liver injury. The role of HSCT in early SCD hepatopathies also deserves evaluation. In advanced SCD hepatopathies, </span></span></span>liver transplantation<span>, which has been rarely performed so far, is the only therapeutic option associated with improved survival. It should definitely be discussed- either electively in case of decompensation in SCD cirrhosis<span> or jaundice/recurrent cholangitis<span> in cholestatic diseases, with excellent outcome, - or emergently in case of ALF or ACLF with more mitigate results.</span></span></span></span></p><p>To improve knowledge and management of SCD liver diseases, creation of national and international registries, as well as longitudinal observational cohorts are encouraged.</p></div>","PeriodicalId":20530,"journal":{"name":"Presse Medicale","volume":"52 4","pages":"Article 104212"},"PeriodicalIF":2.7,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138047814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Presentation of polymyalgia rheumatica and large joint polyarthritis in the spectrum of hyper-IgG4-related disease: A case report and literature review","authors":"Remi Roeland ,&nbsp;Marine Trenec ,&nbsp;Samuel Deshayes ,&nbsp;Hubert de Boysson ,&nbsp;Kevin Prigent ,&nbsp;Achille Aouba","doi":"10.1016/j.lpm.2023.104206","DOIUrl":"10.1016/j.lpm.2023.104206","url":null,"abstract":"","PeriodicalId":20530,"journal":{"name":"Presse Medicale","volume":"52 4","pages":"Article 104206"},"PeriodicalIF":2.7,"publicationDate":"2023-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138047811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}